UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (2575) 2575
male (2558) 2558
animals (2517) 2517
life sciences & biomedicine (2483) 2483
pyrrolidines - pharmacology (2005) 2005
humans (1896) 1896
rats (1467) 1467
female (1341) 1341
pyrrolidines - administration & dosage (1123) 1123
pharmacology & pharmacy (982) 982
pyrrolidines - therapeutic use (838) 838
adult (707) 707
middle aged (690) 690
dose-response relationship, drug (665) 665
mice (629) 629
neurosciences & neurology (614) 614
neurosciences (597) 597
rats, sprague-dawley (557) 557
aged (435) 435
administration, oral (415) 415
pyrrolidines - adverse effects (394) 394
time factors (381) 381
pyrrolidines - pharmacokinetics (378) 378
3,4-dichloro-n-methyl-n--cyclohexyl (362) 362
adamantane - analogs & derivatives (353) 353
pyrrolidines - chemistry (301) 301
rats, wistar (299) 299
treatment outcome (280) 280
abridged index medicus (272) 272
double-blind method (269) 269
analgesics - pharmacology (264) 264
diabetes mellitus, type 2 - drug therapy (259) 259
disease models, animal (257) 257
pyrrolidines (256) 256
endocrinology & metabolism (241) 241
receptors, opioid, kappa - agonists (241) 241
pyrrolidines - metabolism (231) 231
analysis (229) 229
rats, inbred strains (209) 209
psychiatry (198) 198
research (193) 193
rodents (193) 193
morphine - pharmacology (192) 192
adolescent (185) 185
biochemistry & molecular biology (182) 182
vildagliptin (179) 179
adamantane - therapeutic use (174) 174
chemistry (173) 173
type 2 diabetes (173) 173
blood pressure - drug effects (170) 170
nitriles - therapeutic use (168) 168
thiocarbamates - pharmacology (166) 166
drug therapy, combination (163) 163
motor activity - drug effects (160) 160
brain - metabolism (158) 158
care and treatment (158) 158
cardiovascular system & cardiology (152) 152
dopamine (152) 152
drug therapy (151) 151
physical sciences (151) 151
injections, intravenous (150) 150
drug interactions (149) 149
behavior, animal - drug effects (146) 146
oncology (146) 146
dopamine - metabolism (144) 144
brain - drug effects (141) 141
hypoglycemic agents - therapeutic use (140) 140
diabetes (139) 139
dogs (139) 139
heart rate - drug effects (139) 139
kinetics (138) 138
clinical trials as topic (137) 137
research article (136) 136
dipeptidyl-peptidase iv inhibitors - therapeutic use (135) 135
drug administration schedule (135) 135
mice, inbred c57bl (131) 131
naloxone - pharmacology (131) 131
nitriles - administration & dosage (131) 131
naltrexone - pharmacology (130) 130
adamantane - administration & dosage (129) 129
in vitro techniques (129) 129
pharmacology/toxicology (129) 129
injections, intraventricular (128) 128
pyrrolidines - blood (126) 126
nitriles - pharmacology (124) 124
young adult (124) 124
medicine & public health (123) 123
clinical neurology (121) 121
pyrrolidine dithiocarbamate (120) 120
receptors, opioid, kappa (120) 120
pyrrolidines - toxicity (118) 118
benzeneacetamides (117) 117
health aspects (115) 115
structure-activity relationship (115) 115
adamantane - pharmacology (114) 114
naltrexone - analogs & derivatives (113) 113
receptors, dopamine d2 - metabolism (113) 113
nf-kappa b - metabolism (112) 112
physiological aspects (112) 112
biomedicine (111) 111
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3964) 3964
French (68) 68
German (54) 54
Japanese (48) 48
Italian (30) 30
Russian (25) 25
Spanish (12) 12
Chinese (7) 7
Portuguese (6) 6
Hungarian (4) 4
Polish (3) 3
Swedish (3) 3
Danish (2) 2
Bulgarian (1) 1
Czech (1) 1
Dutch (1) 1
Romanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 11/2019, Volume 394, Issue 10212, pp. 1940 - 1948
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct the basic defect caused by CFTR mutations. Improvements in health outcomes have... 
Double-Blind Method | Humans | yes | Pyridines/administration & dosage | Male | Pyrazoles/administration & dosage | Indoles/administration & dosage | Aminophenols/administration & dosage | Cystic Fibrosis Transmembrane Conductance Regulator/genetics | Cystic Fibrosis/drug therapy | Quinolones/administration & dosage | Adolescent | Sweat/chemistry | Female | Benzodioxoles/administration & dosage | Chloride Channel Agonists/administration & dosage | Drug Therapy, Combination | Child | Pyrrolidines/administration & dosage | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Chloride Channel Agonists - adverse effects | Benzodioxoles - administration & dosage | Aminophenols - adverse effects | Indoles - administration & dosage | Sweat - chemistry | Pyridines - adverse effects | Quinolones - adverse effects | Benzodioxoles - adverse effects | Pyrazoles - adverse effects | Pyridines - administration & dosage | Pyrazoles - administration & dosage | Quinolones - administration & dosage | Indoles - adverse effects | Chloride Channel Agonists - administration & dosage | Cystic Fibrosis - genetics | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Aminophenols - administration & dosage | Cystic Fibrosis - drug therapy | Clinical trials | Cystic fibrosis | Ivacaftor | Genetic aspects | Infections | Modulators | Defects | Quality of life | Resistance | Proteins | Randomization | Chloride | Chlorides | Fibrosis | Conductance | Mutation | Safety | Sweat | Active control | Index Medicus | Abridged Index Medicus
Journal Article
Psychopharmacology, ISSN 0033-3158, 2/2017, Volume 234, Issue 4, pp. 589 - 598
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2019, Volume 381, Issue 19, pp. 1809 - 1819
Triple treatment with elexacaftor, tezacaftor, and ivacaftor in patients with cystic fibrosis who had one Phe508del allele and a minimal-function mutation... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cystic Fibrosis - physiopathology | Humans | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Male | Chloride Channel Agonists - adverse effects | Benzodioxoles - administration & dosage | Aminophenols - adverse effects | Indoles - administration & dosage | Forced Expiratory Volume | Sweat - chemistry | Young Adult | Pyridines - adverse effects | Quinolones - adverse effects | Adult | Benzodioxoles - adverse effects | Female | Child | Pyrazoles - adverse effects | Pyridines - administration & dosage | Double-Blind Method | Genotype | Chlorides - analysis | Pyrazoles - administration & dosage | Quinolones - administration & dosage | Indoles - adverse effects | Chloride Channel Agonists - administration & dosage | Cystic Fibrosis - genetics | Adolescent | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Mutation | Aminophenols - administration & dosage | Cystic Fibrosis - drug therapy | Drug Combinations | Cystic fibrosis | Ivacaftor | Genetic aspects | Drug therapy | Patient outcomes | Statistical analysis | Stock options | Clinical trials | Patients | Clinical outcomes | Quality of life | Proteins | Collaboration | Conductance | Genotypes | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Journal of hepatology, ISSN 0168-8278, 08/2017, Volume 67, Issue 2, pp. 263 - 271
Journal Article
Digestive diseases and sciences, ISSN 0163-2116, 6/2014, Volume 59, Issue 6, pp. 1286 - 1295
Journal Article
Current drug targets, ISSN 1389-4501, 2009, Volume 10, Issue 1, pp. 71 - 87
Dipeptidyl peptidase IV (DPP IV) is a key regulator of insulin-stimulating hormones, glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic... 
T2DM | GLP-1 | Developmental progress | Alogliptin | Sitagliptin | Selectivity | Vildagliptin | DPP IV | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Triazoles - administration & dosage | Triazoles - adverse effects | Drugs, Investigational - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Pyrazines - administration & dosage | Drugs, Investigational - therapeutic use | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Substrate Specificity | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Nitriles - administration & dosage | Dipeptidyl Peptidase 4 - adverse effects | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Diabetes Mellitus, Type 2 - enzymology | Treatment Outcome | Clinical Trials as Topic | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Animals | Pyrazines - adverse effects | Drugs, Investigational - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Hypoglycemic Agents - adverse effects | Nitriles - therapeutic use
Journal Article